Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Phase 1/2 Terminated
19 enrolled 11 charts
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 1/2 Terminated
42 enrolled
TEM-GU
Phase 1/2 Terminated
10 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 Terminated
120 enrolled
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Phase 1/2 Terminated
66 enrolled
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma
Phase 1/2 Terminated
3 enrolled 8 charts
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase 1/2 Terminated
252 enrolled 67 charts
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase 1/2 Terminated
72 enrolled
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
Phase 1/2 Terminated
63 enrolled
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Terminated
118 enrolled 18 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
Phase 1/2 Terminated
9 enrolled 10 charts
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Phase 1/2 Terminated
26 enrolled 11 charts
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Phase 1/2 Terminated
20 enrolled
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase 1/2 Terminated
33 enrolled 14 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
Phase 1/2 Terminated
5 enrolled 9 charts
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Phase 1/2 Terminated
14 enrolled 8 charts
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Phase 1/2 Terminated
7 enrolled 10 charts
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Phase 1/2 Terminated
173 enrolled 17 charts
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Phase 1/2 Terminated
24 enrolled 12 charts
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Phase 1/2 Terminated
16 enrolled 13 charts
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase 1/2 Terminated
3 enrolled 1 chart
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Phase 1/2 Terminated
92 enrolled
NivoPlus
Phase 1/2 Terminated
33 enrolled
5-AZ
Phase 1/2 Terminated
11 enrolled 10 charts
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
Phase 1/2 Terminated
1 enrolled 4 charts
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Phase 1/2 Terminated
10 enrolled
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Phase 1/2 Terminated
10 enrolled 8 charts
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 1/2 Terminated
9 enrolled 13 charts
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Terminated
5 enrolled 7 charts
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
Phase 1/2 Terminated
124 enrolled